Skip to main content
. 2019 Jun 7;5(5):372–377. doi: 10.1016/j.ijwd.2019.05.008

Table 1.

Baseline characteristics of pemphigus vulgaris patients receiving rituximab: Newly diagnosed (group A) and relapsed (group B) patients

Variable Group A (n = 37) Group B (n = 38) p-value
Sex
Male (%) 11 (29.7) 15 (29.5) .382
Female (%) 26 (70.3) 23 (60.5)
Disease phenotype (%) .047
Mucosal 12 (32.4) 4 (10.5)
Cutaneous 1 (2.7) 2 (5.3)
Mucocutaneous 24 (64.9) 32 (84.2)
Age at treatment ± standard deviation (range) 38.95 ± 9.70 (20-59) 44.03 ± 11.44 (20-66) .042